ArticleMolecular cancer therapeutics2013

BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.

Bercin Kutluk Cenik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.